Chi, K. N., Saad, F., Ding, K., Bauman, G., Emmenegger, U., Hotte, S. J., Pouliot, F., Lee, J., Beauregard, J., Nappi, L., Kollmannsberger, C. K., Hamilou, Z., Abikhzer, G., Pavic, M., North, S. A., Jiang, D. M., Yip, S., Dellar, C., Parulekar, W. R., Bénard, F. (2026). Canadian Cancer Trials Group (CCTG) study PR21 (PLUDO): Results of crossover treatment from a randomized trial of 177 Lu-PSMA-617 (LuP) vs docetaxel (DOC) in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.5019